Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward patient-focused studies after reporting favorable safety results from Phase 1 clinical trials. The company announced that Phase 1 studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting progression into trials involving individuals living with multiple sclerosis.
In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, a key regulatory step that paves the way for a planned Phase 2 clinical trial. The therapy is designed to target demyelination and protect or restore myelin integrity, a core pathological feature of multiple sclerosis. Unlike many existing treatments that focus on immune modulation, LUCID-MS aims to directly address myelin loss and neurodegeneration, potentially offering a differentiated, first-in-class approach.
To support the clinical program, Quantum BioPharma is planning a partnership with Allucent, a clinical research organization, and engaging neurological specialists. These efforts are intended to strengthen operational support for the LUCID-MS development program.
The company believes that LUCID-MS may provide a novel therapeutic option for multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. Current therapies primarily target the immune system to reduce inflammation, but they do not directly repair myelin damage. LUCID-MS's mechanism of action—preventing and reversing myelin degradation—has shown promise in preclinical models, and the positive Phase 1 safety data marks a significant milestone toward clinical validation.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing LUCID-MS as a patented new chemical entity. The company also has a stake in Unbuzzd Wellness Inc., which markets an over-the-counter version of its alcohol misuse product, with Quantum BioPharma retaining a 19.84% ownership interest and royalty payments.
The advancement of LUCID-MS into Phase 2 trials represents a critical step for patients with multiple sclerosis who currently have limited options for neuroprotection and myelin repair. If successful, the therapy could change the treatment landscape by addressing the underlying neurodegeneration that leads to disability progression.
More information about Quantum BioPharma and its pipeline is available in the company’s newsroom at https://ibn.fm/QNTM. The full article detailing this development can be accessed at https://ibn.fm/AUhNl.
